A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | Product name | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T76888 | Quetmolimab | 2084037-83-0 | 98% |
Quetmolimab
|
Quetmolimab is a humanized monoclonal antibody targeting chemokine ligand 1 (CX3CL1) that can be used to study rheumatoid arthritis. | ||||
T76890 | Petosemtamab | 2213450-26-9 | 98% |
Petosemtamab
|
Petosemtamab (MCLA 158) is a highly potent monoclonal antibody against EGFR (Kd: 0.22 nM) and LGR5 (Kd: 0.86 nM). Petosemtamab promotes EGFR signaling disruption... | ||||
T76891 | Oxelumab | 1186098-83-8 | 98% |
Oxelumab
|
Oxelumab (R 4930) is a human monoclonal antibody for OX40L. Oxelumab could be used to study asthma. | ||||
T76892 | Ordesekimab | 879293-15-9 | 98% |
Ordesekimab
|
Ordesekimab (AMG 714) is a human IgG1 κ-anti-IL-15 (Interleukin Related) monoclonal antibody. Ordesekimab binds competitively to IL-15, inhibiting the interactio... | ||||
T76896 | Abrezekimab | 2043952-59-4 | 98% |
Abrezekimab
|
Abrezekimab (VR 942) is composed of CDP7766, leucine, and trehalose. Abrezekimab is a humanized antibody that targets human IL-13. Abrezekimab inhibits binding t... | ||||
T76907 | Palivizumab | 188039-54-5 | 98% |
|
Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and... | ||||
T76910 | Astegolimab | 2173054-79-8 | 98% |
|
Astegolimab (RG 6149) is a humanised IgG2 monoclonal antibody that targets the IL-33 receptor and inhibits IL-33 signalling. Astegolimab is used in the study of ... | ||||
T76924 | Efalizumab | 214745-43-4 | 98% |
Efalizumab
|
Efalizumab, a novel potent regulator of T cells, is a humanized LFA-1 α subunit (CD11a) monoclonal antibody. Efalizumab has inhibitory effects on T cell activati... | ||||
T76927 | Bersanlimab | 1987854-08-9 | 98% |
|
Bersanlimab (BI-505) is a fully human monoclonal antibody targeting Intercellular Adhesion Molecule-1 (ICAM-1).Bersanlimab has anticancer properties and can be u... | ||||
T76941 | Carotuximab | 1268714-50-6 | 98% |
Carotuximab
|
Carotuximab (DE-122) is a novel endocholine antibody with strong antiangiogenic and anti-inflammatory activity. Carotuximab blocks endothelial glycoprotein (CD10... | ||||
T76956 | Vixarelimab | 2243320-83-2 | 98% |
|
Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor and inhibition of IL-31 and OSM... | ||||
T76957 | Belimumab | 356547-88-1 | 98% |
|
Belimumab(LymphoStat B) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF).Belimumab is used in the study of fatigue and in the t... | ||||
T76975 | Tomaralimab | 1449294-76-1 | 98% |
Tomaralimab
|
Tomaralimab (OPN-305) is a humanized IgG4 monoclonal antibody targeting TLR2. Tomarlimab is used to study myelodysplastic syndromes (MDS). | ||||
T76978 | Siltuximab | 541502-14-1 | 98% |
Siltuximab
|
Siltuximab(CNTO-328) is a monoclonal antibody with anti-tumor activity targeting IL-6 for the study of giant lymph node hyperplasia (MCD) and COVID-19. | ||||
T76992 | Suptavumab | 1629615-23-1 | 98% |
Suptavumab
|
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab neutralizes conserved epitopes on subtypes A and B on RSV. Suptavumab can be used to study RSV i... | ||||
T77011 | Flanvotumab | 1188277-05-5 | 98% |
|
Flanvotumab (IMC-20D7S) is a humanized monoclonal antibody directed against tyrosinase-related protein (TYRP1).Flanvotumab exhibits potent antitumor activity and... | ||||
T77018 | Garadacimab | 2162134-62-3 | 98% |
Garadacimab
|
Garadacimab (CSL312) is a potent whole-human IgG4 monoclonal antibody targeting activation factor XII (FXIIa). Garadacimab can be used to study hereditary angioe... | ||||
T77019 | Garetosmab | 2097125-54-5 | 98% |
Garetosmab
|
Garetosmab (REGN 2477) is A whole-human IgG4 monoclonal antibody that selectively inhibits activin A and acts on COVID-19 44. Garetosmab has potential anti-cance... | ||||
T77042 | Aducanumab | 1384260-65-4 | 98% |
Aducanumab
|
Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Aβ). Aducanumab shows brai... | ||||
T77045 | Itepekimab | 2226742-52-3 | 98% |
|
Itepekimab (REGN-3500) is a potent monoclonal antibody against IL-33.Itepekimab reduces airway inflammation and associated tissue damage in in vivo experiments a... |